CN102648003B - 选择性裂解的全细胞疫苗 - Google Patents

选择性裂解的全细胞疫苗 Download PDF

Info

Publication number
CN102648003B
CN102648003B CN201080055928.XA CN201080055928A CN102648003B CN 102648003 B CN102648003 B CN 102648003B CN 201080055928 A CN201080055928 A CN 201080055928A CN 102648003 B CN102648003 B CN 102648003B
Authority
CN
China
Prior art keywords
reagent
vaccine
wcc
wcb
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080055928.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN102648003A (zh
Inventor
理查德·马利
波特·安德森
陆英杰
马克·奥尔德森
乔治·A·罗伯逊
让-弗朗索瓦斯·卢西恩·迈松纳夫
安德烈亚·马里亚·泰特
瓦尔德里·德奥利韦拉·迪亚斯
维维亚娜·迈蒙里·贡萨尔维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UNDACAO BUTANTAN
Boston Childrens Hospital
PATH VACCINE SOLUTIONS
Original Assignee
UNDACAO BUTANTAN
Boston Childrens Hospital
PATH VACCINE SOLUTIONS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNDACAO BUTANTAN, Boston Childrens Hospital, PATH VACCINE SOLUTIONS filed Critical UNDACAO BUTANTAN
Publication of CN102648003A publication Critical patent/CN102648003A/zh
Application granted granted Critical
Publication of CN102648003B publication Critical patent/CN102648003B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201080055928.XA 2009-10-09 2010-10-12 选择性裂解的全细胞疫苗 Active CN102648003B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25034809P 2009-10-09 2009-10-09
US61/250,348 2009-10-09
US38042910P 2010-09-07 2010-09-07
US61/380,429 2010-09-07
PCT/US2010/052298 WO2011044576A2 (en) 2009-10-09 2010-10-12 Selectively disrupted whole-cell vaccine

Publications (2)

Publication Number Publication Date
CN102648003A CN102648003A (zh) 2012-08-22
CN102648003B true CN102648003B (zh) 2016-01-13

Family

ID=43857436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080055928.XA Active CN102648003B (zh) 2009-10-09 2010-10-12 选择性裂解的全细胞疫苗

Country Status (5)

Country Link
US (1) US9827299B2 (enExample)
EP (1) EP2485764A4 (enExample)
CN (1) CN102648003B (enExample)
IN (1) IN2012DN03418A (enExample)
WO (1) WO2011044576A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011112906A2 (en) 2010-03-12 2011-09-15 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
JPWO2012157699A1 (ja) * 2011-05-18 2014-07-31 味の素株式会社 動物用免疫賦活剤、それを含む飼料及びその製造方法
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
JP2021535921A (ja) 2018-09-12 2021-12-23 アフィニバックス、インコーポレイテッド 多価肺炎球菌ワクチン
EP4164684A4 (en) * 2020-06-12 2024-11-20 Schossau, Tom M. Inactivation of genome enveloped within coronavirus spherical or pleomorphic particles or shells to form a vaccine
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
CN117756959B (zh) * 2024-02-22 2024-05-14 北京民海生物科技有限公司 一种肺炎链球菌荚膜多糖的制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6612233A (enExample) * 1966-08-30 1968-03-01
NL7012832A (enExample) * 1970-08-29 1972-03-02
US3852420A (en) * 1971-01-20 1974-12-03 Richardson Merrell Inc Equine strangles vaccine and method of preparing and using the same
FR2174745A1 (en) * 1972-03-09 1973-10-19 Inst Elevage Med Vet Mixed veterinary vaccine - active against symptomatic and bacterial anthrax
US3920811A (en) * 1972-12-22 1975-11-18 Cutter Lab Adjuvant compositions
US4675176A (en) 1983-12-12 1987-06-23 Norden Laboratories Moraxella bovis protease vaccine
US5281392A (en) * 1986-03-10 1994-01-25 Rubinstein Alan I Method for disinfecting red blood cells, blood products, and corneas
DE3715840A1 (de) * 1987-05-12 1988-12-01 Boehringer Mannheim Gmbh Fuer ein lytisch wirksames, chimaeres protein kodierende rekombinante dna und ihre verwendung
GB8906795D0 (en) * 1989-03-23 1989-05-10 Carroll Noel Method of preparing vaccines
ES2075221T3 (es) * 1989-10-06 1995-10-01 Janos Szabo Proceso para la preparacion de una composicion farmaceutica para el tratamiento de las enfermedades de la piel, especialmente las dermatitis piogenas y atopicas.
US5418130A (en) 1990-04-16 1995-05-23 Cryopharm Corporation Method of inactivation of viral and bacterial blood contaminants
ES2084057T3 (es) 1990-06-07 1996-05-01 Bayer Ag Bacterina para el tratamiento de enfermedades causadas por f. necrophorum y procedimiento para su produccion.
US6042838A (en) 1991-02-15 2000-03-28 Uab Research Foundation immunogenic compositions for mucosal administration of pneumococcal surface protein A (PspA)
AU4114893A (en) * 1992-04-27 1993-11-29 Michigan State University Method for producing a bacterial vaccine and novel vaccines produced thereby
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
AUPN175495A0 (en) * 1995-03-14 1995-04-13 University Of New England, The Method and composition for the prevention of the over production of acid
US6743430B1 (en) * 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
DE19603649A1 (de) * 1996-02-01 1997-08-07 Werner Lubitz Rekombinante Expression von S-Layer-Proteinen
WO1998018931A2 (en) * 1996-10-31 1998-05-07 Human Genome Sciences, Inc. Streptococcus pneumoniae polynucleotides and sequences
IT1296148B1 (it) * 1996-11-22 1999-06-09 Renata Maria Anna Ve Cavaliere Uso di batteri lattici per accrescere il livello delle ceramidi della pelle e delle mucose, e composizioni dermatologiche e cosmetiche atte
US6416959B1 (en) * 1997-02-27 2002-07-09 Kenneth Giuliano System for cell-based screening
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US5958414A (en) 1997-09-03 1999-09-28 Heska Corporation Composition to protect a mammal against Bartonella henselae infection
BR9812976A (pt) 1997-10-20 2000-08-08 Bayer Ag Vacina de neospora
US7172762B1 (en) 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
CA2390613A1 (en) 1999-11-08 2001-05-17 Biomune Vaccines for mycoplasma bovis and methods of use
DE10003241A1 (de) * 2000-01-26 2001-08-02 Werner Lubitz Verschließen von Bakterienghosts
US6378677B1 (en) * 2000-10-03 2002-04-30 Honda Giken Kogyo Kabushiki Kaisha Power transmission device having electromagnetic clutch
JP2006512401A (ja) * 2001-06-05 2006-04-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ナノエマルジョンワクチン
AU2002314626B2 (en) * 2001-06-11 2008-01-03 Applied Nanosystems B.V. Methods for binding AcmA-type protein anchor fusions to cell-wall material of micro-organisms
US7399476B2 (en) 2001-07-11 2008-07-15 Werner Lubitz Nucleic acid free ghost preparations
CN102172406B (zh) * 2001-10-15 2013-03-13 恩吉尼克分子传递私人有限公司 用作体外和体内dna转染与基因治疗载体的完整微细胞
US20060121058A1 (en) * 2002-08-08 2006-06-08 Children's Medical Center Corporation Anti-pneumococcal preparations
EP1618884A1 (en) * 2003-04-28 2006-01-25 Sekisui Chemical Co., Ltd. Instrument for inducing cytokine and method of inducing cytokine
US7204993B2 (en) * 2004-03-18 2007-04-17 The United States Of America As Represented By The Secretary Of Agriculture Streptococcus agalactiae vaccine
US7211428B1 (en) * 2004-05-18 2007-05-01 Council Of Scientific And Industrial Research Strain of Bacillus as a bioinoculant
US7291276B1 (en) * 2004-06-21 2007-11-06 Winston Company, Inc. Controlled production and release of oxygen activated biocide into holding tanks for RV's, boats and the like
US20060003454A1 (en) * 2004-07-02 2006-01-05 Conjugon, Inc. Non-dividing donor cells for gene transfer
ATE526978T1 (de) 2004-08-17 2011-10-15 Hunter Immunology Ltd Verfahren zur herstellung von oral abgetöteten vakzinen
AU2005316041B2 (en) * 2004-12-14 2010-06-24 Alk Abello A/S Pharmaceutical composition comprising a bacterial cell displaying a heterologous proteinaceous compound
WO2006107097A1 (ja) * 2005-04-01 2006-10-12 Riken 経鼻ワクチン
EP2371843B1 (en) * 2005-05-19 2014-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Functional epitopes of streptococcus pneumoniae psaA antigen and uses thereof
EP1746103A1 (en) * 2005-07-20 2007-01-24 Applied NanoSystems B.V. Bifunctional protein anchors
ES2423663T3 (es) * 2005-08-08 2013-09-23 Oregon Health And Science University Inactivación de patógenos con peróxido de hidrógeno para la producción de vacunas
CN101365480B (zh) 2005-11-01 2014-11-05 诺华疫苗和诊断有限两合公司 经由β-丙内酯处理的残留细胞DNA水平降低的细胞衍生病毒疫苗
US20110172826A1 (en) * 2005-12-14 2011-07-14 Amodei Dario G Device including altered microorganisms, and methods and systems of use
WO2008008092A2 (en) * 2006-07-10 2008-01-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Campylobacter pilus protein, compositions and methods
JP5249326B2 (ja) * 2007-07-23 2013-07-31 ワクチン リサーチ インターナショナル ピーエルシー 不活化ブドウ球菌全細胞ワクチン
JP5722782B2 (ja) * 2008-09-26 2015-05-27 ナノバイオ コーポレーション ナノエマルジョン治療用組成物及びその使用方法
TW201043242A (en) * 2009-03-26 2010-12-16 Intervet Int Bv Vaccine for protection against Streptococcus suis bacteria of various serotypes
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
US8668911B2 (en) * 2009-05-14 2014-03-11 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
CN107213461B (zh) * 2009-09-10 2022-03-15 勃林格殷格翰动物保健美国公司 包含含有皂苷的佐剂的新疫苗制剂
JP2013512692A (ja) * 2009-12-07 2013-04-18 シナプティック リサーチ，リミテッド ライアビリティ カンパニー プロテアーゼ活性阻害剤の同定とプロテアーゼ活性の存在を測定するための方法

Also Published As

Publication number Publication date
WO2011044576A2 (en) 2011-04-14
US9827299B2 (en) 2017-11-28
EP2485764A4 (en) 2014-01-29
IN2012DN03418A (enExample) 2015-10-23
EP2485764A2 (en) 2012-08-15
US20120251577A1 (en) 2012-10-04
CN102648003A (zh) 2012-08-22
WO2011044576A3 (en) 2011-08-18

Similar Documents

Publication Publication Date Title
Friedlander et al. Anthrax vaccines
CN102648003B (zh) 选择性裂解的全细胞疫苗
Brey Molecular basis for improved anthrax vaccines
JP5931724B2 (ja) ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｎｅｕｍｏｎｉａｅに対するワクチンおよび組成物
RU2623174C2 (ru) Вакцины и композиции против streptococcus pneumoniae
US7914802B2 (en) Mucosal vaccine adjuvants containing bacterial flagellins as an active component
JP2012501959A (ja) Ｙｅｒｓｉｎｉａｐｅｓｔｉｓ抗原を含む組成物
DK2544711T3 (en) Treatment of streptococcal infections
Schulze et al. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection
US20060002960A1 (en) GM1 binding deficient exotoxins for use as immunoadjuvants
JP2024540918A (ja) リポ多糖（ｌｐｓ）欠損アシネトバクター・バウマニ多価ワクチン
JP2015533491A (ja) 染色体組換え操作に基づく多機能性経口ワクチン
KR101130884B1 (ko) 패혈증 비브리오균의 플라젤린과 병원체의 항원 단백질을 융합시켜 제조한 재조합 융합 단백질 및 이를 유효성분으로 포함하는 점막 투여용 백신
Baumann Mucosal vaccination against bacterial respiratory infections
Olivera et al. Immunization with the recombinant Cholera toxin B fused to Fimbria 2 protein protects against Bordetella pertussis infection
US9310381B2 (en) Engineered type IV pilin of Clostridium difficile
JP2022179236A (ja) 連鎖球菌ワクチン製剤およびその使用
US9119803B2 (en) Carious tooth vaccine and preparation method
CA2543080C (en) Compositions and methods for activating innate and allergic immunity
JP2018135388A (ja) シュードモナス抗原および抗原の組み合わせ
US10293041B2 (en) Multivalent stable vaccine composition and methods of making same
Chakraborty et al. Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity
Lycke Mechanisms of adjuvant action
AU2004235815A1 (en) Vaccinating against infectious diseases using proteosomes
WO2025252927A1 (en) Vaccine compositions and methods and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant